IDEXX Laboratories, Inc. $IDXX Shares Purchased by Intech Investment Management LLC

Intech Investment Management LLC boosted its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 188.0% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 30,224 shares of the company’s stock after acquiring an additional 19,731 shares during the period. Intech Investment Management LLC’s holdings in IDEXX Laboratories were worth $15,783,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in IDXX. Bank of New York Mellon Corp acquired a new stake in IDEXX Laboratories during the 2nd quarter worth approximately $628,223,000. Arrowstreet Capital Limited Partnership grew its stake in shares of IDEXX Laboratories by 52.4% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 838,839 shares of the company’s stock valued at $471,335,000 after purchasing an additional 288,471 shares during the last quarter. International Assets Investment Management LLC grew its stake in shares of IDEXX Laboratories by 30,484.1% in the 3rd quarter. International Assets Investment Management LLC now owns 234,274 shares of the company’s stock valued at $122,336,000 after purchasing an additional 233,508 shares during the last quarter. Alyeska Investment Group L.P. increased its holdings in shares of IDEXX Laboratories by 97.3% in the second quarter. Alyeska Investment Group L.P. now owns 401,082 shares of the company’s stock valued at $211,146,000 after purchasing an additional 197,808 shares during the period. Finally, American Capital Management Inc. acquired a new position in shares of IDEXX Laboratories in the second quarter valued at approximately $85,341,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on IDXX. Citigroup upped their price target on IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 5th. UBS Group lifted their price objective on shares of IDEXX Laboratories from $627.00 to $700.00 and gave the company a “neutral” rating in a research report on Tuesday, November 3rd. The Goldman Sachs Group assumed coverage on shares of IDEXX Laboratories in a research report on Friday, October 16th. They issued a “buy” rating and a $740.00 price objective on the stock. Weiss Ratings raised shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, October 8th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of IDEXX Laboratories from $775.00 to $750.00 and set an “overweight” rating on the stock in a research note on Friday, October 16th. Seven equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $717.27.

View Our Latest Stock Analysis on IDEXX Laboratories

Insiders Place Their Bets

In related news, EVP Michael Lane sold 3,979 shares of IDEXX Laboratories stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $688.64, for a total value of $2,740,098.56. Following the sale, the executive vice president directly owned 4,076 shares in the company, valued at $2,806,896.64. The trade was a 49.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Lawrence D. Kingsley sold 2,203 shares of the company’s stock in a transaction on Friday, September 4th. The stock was sold at an average price of $532.08, for a total value of $1,172,172.24. Following the transaction, the director directly owned 9,568 shares in the company, valued at $5,090,941.44. This represents a 18.72% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 41,428 shares of company stock worth $28,567,934. Corporate insiders own 0.79% of the company’s stock.

IDEXX Laboratories Price Performance

Shares of NASDAQ:IDXX opened at $700.65 on Tuesday. The company has a quick ratio of 0.88, a current ratio of 1.19 and a debt-to-equity ratio of 0.16. The company has a market cap of $55.20 billion, a P/E ratio of 47.25 and a beta of 1.55. IDEXX Laboratories, Inc. has a 52 week low of $500.61 and a 52 week high of $769.98. The company has a 50-day moving average price of $565.71 and a 200 day moving average price of $573.58.

IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last released its earnings results on Monday, November 2nd. The company reported $3.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.71 by $0.25. The company had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.19 billion. IDEXX Laboratories had a return on equity of 71.04% and a net margin of 25.36%. The firm’s quarterly revenue was up 9.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.22 EPS. Research analysts predict that IDEXX Laboratories, Inc. will post 15.05 earnings per share for the current year.

IDEXX Laboratories Profile

(Free Report)

IDEXX Laboratories develops and sells diagnostic, technology and software products for veterinary, livestock and water-testing markets. Its veterinary offerings include in-clinic diagnostic instruments and tests, reference laboratory services, digital imaging and practice-management software that help veterinary professionals assess animal health and manage their practices. The company also provides diagnostic tests and related services for livestock and poultry, as well as products used to monitor water quality.

Recommended Stories

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.